ARS Pharmaceuticals, Inc. (SPRY) Misses Q1 EPS by 12c, Beats on Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- S&P 500, Nasdaq advance as oil eases ahead of Fed decision
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- S&P Global explores potential separation of Capital IQ business
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- Equities end higher as Anthropic's IPO filing buoys AI stocks
ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update
May 15, 2026 6:00 AM EDTQ1 2026 total revenue of $22.7 million including neffy® (epinephrine nasal spray) U.S. net product
revenue of $17.5 million
CVS Caremark proposal in final stages of approval process; definitive update anticipated in early June
Sales force expansion to 148 representatives completed
Phase 2b CSU study interim population fully enrolled, and on track for Q4 2026 readout
Conference call to be held today, May 15, 2026, at 5:30 a.m. PT / 8:30 a.m. ET
SAN DIEGO, May 15, 2026 (GLOBE... More



